AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22606361
Drug: High plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High plasma ferritin (>150 µg/L for women and >200 µg/L for men)
Trial: 16047554
Drug: Chunghyul‐dan 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chunghyul‐dan 1200 mg once a day for 2 weeks
Trial: 12145067
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine 100 microg (IT 100 group)
Trial: 12145067
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine 200 microg (IT 200 group)
Trial: 12145067
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine 3 mg (Epidural group)
Trial: 14586167
Drug: Naftidrofuryl (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naftidrofuryl (400 mg)
Trial: 23117550
Drug: Low-dose concentration
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose concentration MSCs (20 million cells)
Trial: 12872612
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination bi-layer tablet (Quadroplus)
Trial: 12872612
Drug: Tablets containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets containing solely spirapril hydrochloride monohydrate (Quadropril)
Trial: 12872612
Drug: Hydrochlorothiazide (produced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (produced exclusively for study medication)
Trial: 11044578
Drug: Androgen receptor
RxNorm normalized name: Androgen receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen receptor mRNA expression in hippocampal tissue
Trial: 8644545
Drug: Prick test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prick test with 10% fluorescein solution
Trial: 8644545
Drug: Prick test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prick test with 1.0% fluorescein solution
Trial: 8644545
Drug: Intradermal skin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal skin test with 10% fluorescein solution
Trial: 8644545
Drug: Intradermal skin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal skin test with 0.1% fluorescein solution
Trial: 6704973
Drug: Autologous tumor
RxNorm normalized name: DNP-Modified autologous tumor vaccine
DrugBank: DNP-Modified autologous tumor vaccine (DB17436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous tumor cells plus Bacillus Calmette‐Guérin vaccine
Trial: 22574591
Drug: Shuxuening Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shuxuening Injection (SI), 15 mL by intravenous dripping, twice daily for 14 days
Trial: 22574591
Drug: Routine therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine therapies for COPD (Control)
Trial: 16013622
Drug: Repeated video
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated video feedback over 3 consecutive weekly practice sessions
Trial: 8959943
Drug: Deferiprone (3-6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferiprone (3-6 g daily)
Trial: 29727906
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg dapagliflozin for one month (TP1)
Trial: 29727906
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg saxagliptin for one month (TP2)
Trial: 29727906
Drug: Dapagliflozin and
RxNorm normalized name: Dapagliflozin and metformin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin and saxagliptin combination
Trial: 24710957
Drug: Rocuronium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.6 mg·kg(‐1) with sugammadex 4.0 mg·kg(‐1)
Trial: 24710957
Drug: Succinylcholine 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine 1.0 mg·kg(‐1)
Trial: 20009394
Drug: Moxifloxacin-based triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin-based triple therapy
Trial: 20009394
Drug: Clarithromycin-based triple
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin-based triple therapy
Trial: 11679006
Drug: tazarotene gel
RxNorm normalized name: Tazarotene
DrugBank: Tazarotene (DB00799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tazarotene gel 0.1%
Trial: 11679006
Drug: diflorasone diacetate
RxNorm normalized name: Diflorasone Diacetate
DrugBank: Diflorasone (DB00223)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: diflorasone diacetate 0.05% ointment
Trial: 11679006
Drug: diflorasone diacetate
RxNorm normalized name: Diflorasone Diacetate
DrugBank: Diflorasone (DB00223)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: diflorasone diacetate 0.05% ointment + tazarotene gel 0.1%
Trial: 9490342
Drug: Neoton (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoton (4 different schemes) administered in the acute period of MI to 97 patients.
Trial: 2977404
Drug: Low-dose captopril
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose captopril (6.25 mg twice daily)
Trial: 2977404
Drug: High-dose captopril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose captopril (25 mg twice daily)
Trial: 24325386
Drug: Carnitine (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carnitine (1000 mg oral solution twice daily for 4 weeks)
Trial: 24325386
Drug: Placebo (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (10 mL oral solution twice daily for 4 weeks)
Trial: 17869987
Drug: Ethylene oxide
RxNorm normalized name: Ethylene oxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethylene oxide sterilization (E1 group - once, E2 group - twice, E3 group - three times)
Trial: 15028552
Drug: Immediate 12-week
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate 12-week parent and child treatment
Trial: 15028552
Drug: Delayed-treatment condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-treatment condition (control)
Trial: 11404721
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (amoxicillin, clarithromycin, pantoprazole)
Trial: 11404721
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (tinidazole, clarithromycin, ranitidine bismuth citrate)
Trial: 11404721
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (tinidazole, clarithromycin, pantoprazole)
Trial: 11404721
Drug: Quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple therapy (tinidazole, tetracycline, bismuth, pantoprazole)
Trial: 11404721
Drug: Triple therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapies
Trial: 11404721
Drug: Daily insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily insulin requirement in re-infected IDDM patients
Trial: 3337028
Drug: Iron-fortified formula
RxNorm normalized name: INFANT FORMULA SMA IRON FORTIFIED CONC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron-fortified formula (1.6 mg Fe/100 kcal)
Trial: 29282469
Drug: Esketamine 84
RxNorm normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Esketamine 84 mg
Trial: 27488675
Drug: VR-CAP (bortezomib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VR-CAP (bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone)
Trial: 23582626
Drug: Benazepril 40
RxNorm normalized name: benazepril 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril 40 mg and Amlodipine 10 mg (B+A)
Trial: 23582626
Drug: Benazepril 40
RxNorm normalized name: benazepril 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril 40 mg and Hydrochlorothiazide 25 mg (B+H)
Trial: 21135284
Drug: Amrubicin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amrubicin (40 mg/m²/d in a 5-minute IV infusion, days 1 through 3, every 21 days)
Trial: 21135284
Drug: Topotecan (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan (1.5 mg/m²/d in a 30-minute IV infusion, days 1 through 5, every 21 days)
Trial: 18766378
Drug: Ethanolic DEET
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanolic DEET solution (25% DEET)
Trial: 10969352
Drug: Not prescribed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not prescribed antiretroviral therapy
Trial: 1438618
Drug: MCPP (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCPP (0.25 mg/kg, p.o.)
Trial: 1438618
Drug: DMI (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMI (75 mg, i.m.)
Trial: 16251172
Drug: Increasing dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing dosage of rh‐EPO up to 5000 U/kg/wk
Trial: 16251172
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy of rh‐EPO at 1250 U/kg/wk
Trial: 11912262
Drug: Angiotensin I
RxNorm normalized name: ANGIOTENSIN I
DrugBank: Angiotensin 1-7 (DB11720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin I infusion (8 ng/kg per min) with liberal sodium intake (200 mmol sodium/d)
Trial: 11912262
Drug: Angiotensin I
RxNorm normalized name: ANGIOTENSIN I
DrugBank: Angiotensin 1-7 (DB11720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin I infusion (8 ng/kg per min) with low sodium intake (50 mmol sodium/d)
Trial: 10444229
Drug: Loratadine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loratadine (10 mg per day)
Trial: 10444229
Drug: Diphenhydramine (first-generation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenhydramine (first-generation antihistamine)
Trial: 7600138
Drug: Flumazenil (1
RxNorm normalized name: Flumazenil (18-F)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (1 mg at 0.1 mg/min infusion rate)
Trial: 631690
Drug: Berotec syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Berotec syrup 2.5 mg
Trial: 631690
Drug: Berotec syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Berotec syrup 5.0 mg
Trial: 30745346
Drug: Mobile augmented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile augmented reality simulator used for local anesthesia training, 2 hours weekly for four weeks.
Trial: 29169472
Drug: Inhaled xenon
RxNorm normalized name: xenon
DrugBank: Xenon (DB13453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled xenon (40% end-tidal concentration) combined with hypothermia (33°C) for 24 hours
Trial: 29169472
Drug: Hypothermia treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypothermia treatment alone
Trial: 24355401
Drug: IOP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IOP treatment as usual (TAU)
Trial: 20865421
Drug: Ranibizumab treatment
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab treatment (first-time)
Trial: 20218030
Drug: Control activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control activity (2 drug-profile reviews)
Trial: 11376174
Drug: No radiotherapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No radiotherapy, second surgery, or chemotherapy
Trial: 9279624
Drug: One or
RxNorm normalized name: Geone Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One or more doses of BCG vaccine
Trial: 9279624
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of BCG vaccine
Trial: 9279624
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of BCG vaccine
Trial: 9279624
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of BCG vaccine
Trial: 25736912
Drug: CHOP-based chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHOP-based chemotherapy
Trial: 2545451
Drug: RIT-4237 rotavirus
RxNorm normalized name: ROTAVIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIT-4237 rotavirus vaccine
Trial: 30698771
Drug: Radial Extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial Extracorporeal Shock Wave Therapy (3 sessions)
Trial: 29119960
Drug: Low-frequency electrostatic
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-frequency electrostatic therapy
Trial: 25850708
Drug: Topical Loteprednol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Loteprednol Etabonate 0.5%
Trial: 19920107
Drug: Pegfilgrastim (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegfilgrastim (100 mcg/kg, single dose)
Trial: 19920107
Drug: Filgrastim (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filgrastim (5 mcg/kg/day, daily until neutrophil recovery)
Trial: 16491284
Drug: Pamidronate treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate treatment (annual dose, 9 mg/kg body weight) for 2-4 years
Trial: 15187818
Drug: Wheat fibre
RxNorm normalized name: triticum (wheat fibre)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat fibre supplementation (10.5 g/day for 1 week, then 21 g/day for 4 weeks)
Trial: 9248263
Drug: 0.5 w/v%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 w/v% black tea extract gargle twice daily (at 8 a.m. and 5 p.m.)
Trial: 8448094
Drug: Low-dose epinephrine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose epinephrine
Trial: 2360502
Drug: Atenolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (50 to 100 mg once daily)
Trial: 2427841
Drug: Celiprolol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celiprolol (200 to 400 mg once daily)
Trial: 25680597
Drug: Pelvic external
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic external beam radiation therapy (EBRT)
Trial: 23553459
Drug: Esomeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole (40 mg, twice daily) for 12 weeks
Trial: 18445988
Drug: imidafenacin 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: imidafenacin 0.1 mg twice daily
Trial: 12756930
Drug: 4 weeks
RxNorm normalized name: risperiDONE 75 mg/4 weeks intramuscular powder for injection, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 weeks of physical therapy (heat application, massage, ultrasound, muscle stretching)
Trial: 12756930
Drug: 6 weeks
RxNorm normalized name: perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6 weeks of physical therapy (heat application, massage, ultrasound, muscle stretching)
Trial: 12756930
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (4 weeks and 6 weeks of physical therapy)
Trial: 12756930
Drug: 4 weeks
RxNorm normalized name: risperiDONE 75 mg/4 weeks intramuscular powder for injection, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 weeks of physical therapy
Trial: 29857780
Drug: 1% N-chlorotaurine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% N-chlorotaurine (NCT) inhaled solution, 1.2 ml over 10 min, once daily for 5 days.
Trial: 29857780
Drug: 0.9% NaCl
RxNorm normalized name: Trace Metals Additive in 0.9% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NaCl (placebo) inhaled solution, 1.2 ml over 10 min, once daily for 5 days.
Trial: 29857780
Drug: 1% N-chlorotaurine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% N-chlorotaurine (NCT) inhaled solution
Trial: 29857780
Drug: 0.9% NaCl
RxNorm normalized name: Trace Metals Additive in 0.9% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NaCl (placebo) inhaled solution
Trial: 27163497
Drug: Orteronel 400
RxNorm normalized name: Orteronel
DrugBank: Orteronel (DB12066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orteronel 400 mg with a low-fat meal
Trial: 27163497
Drug: Orteronel 400
RxNorm normalized name: Orteronel
DrugBank: Orteronel (DB12066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orteronel 400 mg with a high-fat meal
Trial: 27163497
Drug: Orteronel 400
RxNorm normalized name: Orteronel
DrugBank: Orteronel (DB12066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orteronel 400 mg under fasting conditions
Trial: 17653960
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg topical testosterone therapy daily (2 cm Andro‐Feme cream)
Trial: 16173911
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment arms (including control)
Trial: 8084808
Drug: Propranolol 160
RxNorm normalized name: propranolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 160 mg daily
Trial: 15488139
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (medical treatment only)
Trial: 29699518
Drug: Ophthalmic viscosurgical
RxNorm normalized name: Viscoat Ophthalmic Viscosurgical Device Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic viscosurgical device (OVD)
Trial: 27929610
Drug: Ketamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine infusion (0.5 mg/kg over 40 minutes)
Trial: 21734063
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine administered with HPV-16/18 AS04-adjuvanted vaccine (HepB+HPV group)
Trial: 21734063
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine administered alone (HepB group)
Trial: 19712717
Drug: flavored solution
RxNorm normalized name: Benecalorie Unflavored Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: flavored solution consumed prior to 30 min running exercise
Trial: 19712717
Drug: flavored solution
RxNorm normalized name: Benecalorie Unflavored Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: flavored solution merely tasted prior to 30 min running exercise
Trial: 16672064
Drug: Tetracaine 4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracaine 4% gel (1.1 g applied for 30 minutes)
Trial: 16672064
Drug: Placebo (1.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1.1 g applied for 30 minutes)
Trial: 16672064
Drug: Tetracaine 4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracaine 4% gel
Trial: 11230783
Drug: L-NMMA (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NMMA (0.1 mg/kg/min) during insulin infusion
Trial: 11230783
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion (40 mU/m2/min for young, 34 mU/m2/min for old)
Trial: 9259113
Drug: Sulodexide (Sdx,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulodexide (Sdx, 50 mg bid orally for 6 months)
Trial: 9259113
Drug: Pentoxifylline (Ptx,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (Ptx, 400 mg tid orally for six months)
Trial: 576833
Drug: Reproterol (Bronchspasmin)
RxNorm normalized name: reproterol
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reproterol (Bronchspasmin) administered at doses of 3 x 20 mg/day (some patients received 6 x 10 mg/day) for four weeks
Trial: 576833
Drug: Orciprenaline administered
RxNorm normalized name: orciprenaline
DrugBank: Orciprenaline (DB00816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orciprenaline administered at doses of 3 x 20 mg/day (some patients received 6 x 10 mg/day) for four weeks
Trial: 24936126
Drug: ETV 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ETV 0.5 mg daily
Trial: 24936126
Drug: ETV 1
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ETV 1 mg daily
Trial: 7603605
Drug: sCT suppositories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sCT suppositories at the dose of 100 UI/day
Trial: 7603605
Drug: sCT suppositories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sCT suppositories at the dose of 200 UI every other day
Trial: 30893166
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of sublative bipolar fractional radiofrequency (FRF) and 0.1% topical tretinoin
Trial: 2227085
Drug: 0.1% topical
RxNorm normalized name: Halog 0.1% Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% topical tretinoin
Trial: 28416587
Drug: Inhaled long-acting
RxNorm normalized name: Sinex Long-Acting Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled long-acting beta2-agonist (vilanterol 25 µg)
Trial: 28416587
Drug: Inhaled corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroid (fluticasone furoate 100 µg)